Close Menu

Biocartis

Biocartis said this week that Ulrik Cordes has joined the company as chief commercial officer.

Biocartis of Lausanne, Switzerland, has been awarded US Patent No. 8,441,629, "Optical detection system for monitoring rtPCR reaction."

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

Cepheid disclosed in a filing with the US Securities and Exchange Commission this week that it has terminated the employment of Nicolaas Arnold, its executive vice president of worldwide commercial operations.

Molecular diagnostics firm Biocartis has hired Inge Basteleurs as its general counsel.

NEW YORK (GenomeWeb News) – Five years after its founding, Swiss molecular diagnostics firm Biocartis has transitioned to full commercial mode with the launch of its DMAT platform last week and the completion announced today of its Series D financing round bringing in €34.5 million ($45.0 million

Precision Therapeutics Assesses Multi-Gene Predictors of Breast Cancer Chemo Response

NEW YORK (GenomeWeb News) – Immunexpress Group, Biocartis, and Debiopharm Group today announced a collaboration to further develop Immunexpress' gene expression assay for managing sepsis.

Swiss molecular diagnostics firm Biocartis said last week that it is collaborating with the Wellcome Trust Sanger Institute and Philips Research to develop a workflow to extract and amplify circulating tumor DNA from blood samples for downstream analysis on Biocartis' multiplex d

NEW YORK (GenomeWeb News) – Biocartis today announced it is developing a workflow for extracting, amplifying, and detecting tumor DNA on its diagnostic platforms in collaboration with the Wellcome Trust Sanger Institute and Philips Research.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.